EA202090959A1 - Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза - Google Patents

Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза

Info

Publication number
EA202090959A1
EA202090959A1 EA202090959A EA202090959A EA202090959A1 EA 202090959 A1 EA202090959 A1 EA 202090959A1 EA 202090959 A EA202090959 A EA 202090959A EA 202090959 A EA202090959 A EA 202090959A EA 202090959 A1 EA202090959 A1 EA 202090959A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amine
substituted heterocyclic
methods
synthesis
salts
Prior art date
Application number
EA202090959A
Other languages
English (en)
Inventor
Джон Эммерсон Кэмпбелл
Кеннет Уилльям Дункан
Джеймс Эдвард Джон Миллс
Майкл Джон Манчхоф
Original Assignee
Эпизайм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк. filed Critical Эпизайм, Инк.
Publication of EA202090959A1 publication Critical patent/EA202090959A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Настоящее изобретение относится к аминзамещенным гетероциклическим соединениям. Настоящее изобретение также относится к фармацевтическим композициям, содержащим данные соединения, и к способам лечения нарушения (например, рака), осуществляемым путем введения аминзамещенного гетероциклического соединения, раскрытого в данном документе, или фармацевтической композиции на его основе нуждающимся в этом субъектам. Настоящее изобретение также относится к применению таких соединений в исследовательских или других целях, отличных от терапевтических.
EA202090959A 2017-10-18 2018-10-18 Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза EA202090959A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573917P 2017-10-18 2017-10-18
PCT/US2018/056428 WO2019079540A1 (en) 2017-10-18 2018-10-18 AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF

Publications (1)

Publication Number Publication Date
EA202090959A1 true EA202090959A1 (ru) 2020-07-13

Family

ID=66173899

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090959A EA202090959A1 (ru) 2017-10-18 2018-10-18 Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза

Country Status (16)

Country Link
US (2) US20200247790A1 (ru)
EP (1) EP3697762A4 (ru)
JP (2) JP2021500334A (ru)
KR (1) KR20200101330A (ru)
CN (1) CN111417628A (ru)
AU (2) AU2018353122B2 (ru)
BR (1) BR112020007632A2 (ru)
CA (1) CA3079273A1 (ru)
CL (1) CL2020001009A1 (ru)
CO (1) CO2020005944A2 (ru)
EA (1) EA202090959A1 (ru)
IL (2) IL301746A (ru)
MA (1) MA50418A (ru)
MX (1) MX2020007152A (ru)
SG (1) SG11202003225YA (ru)
WO (1) WO2019079540A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019016775A2 (pt) 2017-02-17 2020-03-31 Trevena, Inc. Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
LT3697789T (lt) 2017-10-18 2021-12-10 Incyte Corporation Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
CN114249785B (zh) * 2020-09-23 2024-04-05 常州方圆制药有限公司 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法
WO2022093904A1 (en) * 2020-10-27 2022-05-05 Trevena, Inc. Crystalline and amorphous forms of a delta-opioid modulator

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
MY167260A (en) * 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
US9840500B2 (en) * 2014-06-16 2017-12-12 Fundación Para La Investigación Médica Aplicada Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases
CN106456627A (zh) * 2014-06-23 2017-02-22 基因泰克公司 治疗癌症和预防癌症耐药性的方法
CN109153650A (zh) * 2016-04-15 2019-01-04 Epizyme股份有限公司 作为ehmt1和ehmt2抑制剂的胺取代的芳基或杂芳基化合物
EP4285906A3 (en) * 2016-12-19 2024-03-13 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
IL301746A (en) 2023-05-01
AU2018353122A1 (en) 2020-06-04
EP3697762A1 (en) 2020-08-26
IL273974B1 (en) 2023-04-01
AU2018353122B2 (en) 2023-11-23
EP3697762A4 (en) 2021-04-07
CL2020001009A1 (es) 2020-12-18
MA50418A (fr) 2021-04-07
IL273974A (en) 2020-05-31
SG11202003225YA (en) 2020-05-28
US20200247790A1 (en) 2020-08-06
IL273974B2 (en) 2023-08-01
CO2020005944A2 (es) 2020-07-31
US20220324851A1 (en) 2022-10-13
BR112020007632A2 (pt) 2020-09-29
JP2021500334A (ja) 2021-01-07
WO2019079540A1 (en) 2019-04-25
JP2023036991A (ja) 2023-03-14
MX2020007152A (es) 2020-12-10
CN111417628A (zh) 2020-07-14
KR20200101330A (ko) 2020-08-27
CA3079273A1 (en) 2019-04-25
AU2024201165A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
MX2022010947A (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
MX2019007234A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos.
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA202091711A1 (ru) ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
EA201692470A1 (ru) Фармацевтические комбинации
EA202090414A1 (ru) Соединения и их применение
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина